Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
Conditions
- Prolymphocytic Leukemia
- Recurrent Adult Diffuse Large Cell Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Small Lymphocytic Lymphoma
- Refractory Chronic Lymphocytic Leukemia
Interventions
- DRUG: Selinexor
- DRUG: Ibrutinib
- OTHER: Pharmacological Study
- OTHER: Laboratory Biomarker Analysis
Sponsor
Jennifer Woyach
Collaborators